Edivoxetine fails Phase III trials for Depression-Eli Lilly

Eli Lilly and Company announced that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in Depression after eight weeks of treatment. When added to a selective serotonin reuptake inhibitor , edivoxetine did not separate from placebo on the Montgomery-Asberg Depression Rating Scale in three acute randomized placebo-controlled Phase III studies (LNBM, LNBQ and LNBR). While the safety and tolerability of edivoxetine was consistent with previous studies, the efficacy results do not support a regulatory submission for adjunctive treatment in patients with Major Depressive Disorder . Data from all three studies will be disclosed in appropriate scientific forums in 2014.